PRS-080 demonstrated Anticalins’ ability to encapsulate small targets like hepcidin with specificity and potency.
In the trial, PRS-080 displayed sub-nanomolar potency, which translated into cell-based and in-vivo efficacy.
PRS-080 demonstrated complete inhibition of hepcidin-induced hypoferremia in a dose-dependent manner, in a preclinical model of efficacy.
Pieris CEO Stephen Yoder said their hepcidin antagonist program highlights Pieris’ strategy of pursuing therapeutic programs with meaningful, clinically relevant differentiation over conventional molecules.
"We are aiming to achieve first-in-man readiness no later than the beginning of 2013, which girds this program with first-in-class potential," Yoder said.